Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

How Does Risk Screening for Kidney Disease Influence Diabetes Distress?

Research output: Contribution to journalConference abstract in journalResearchpeer-review

  1. Co-designing an Intervention for Adults with New-Onset Type 1 Diabetes to Improve Psychological and Social Adaptation

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  2. Diabetes Support Needs in People with Severe Mental Illness and Diabetes

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  3. Effects of Dapagliflozin, Metformin or Exercise on Glucose Metabolism in Individuals with Prediabetes: The PRE-D Trial

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  4. Effects of Dapagliflozin, Metformin or Exercise on Markers of Cardiometabolic Risk: The PRE-D Trial

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  1. Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
Background: Screening for future risk of diabetic kidney disease (DKD) in people with type 2 diabetes (T2D) and normal kidney function was conducted in the clinical multicenter intervention trial PRIORITY (Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy In TYpe 2 diabetic patients with normoalbuminuria). Risk screening was based on a urinary proteomic analysis categorizing the patients at high or low risk for DKD. Little is known about how risk-assessments affect patients. However, screening for DKD is likely to increase diabetes distress (DD), as DD is linked to specific diabetes stressors such as worrying about complications.

Aim: To investigate to what extent DD was affected by screening and individualized information about future risk of DKD.

Methods: Of 436 participants in the Danish part of PRIORITY, 217 were asked to complete a full diabetes distress scale (DDS) and 139 completed DDS at screening visit (T1) and after provision of screening results (T2, 6 weeks after T1). DDS was repeated in 84 at a follow-up visit (T3, 12 months after T2). DD differences were explored with wilcoxon signed-rank test and subgroup differences with paired t-test.

Results: Participants’ mean age was 61 years, 37 % women, mean diabetes duration 10 years, mean HbA1c 54mmol/mol, 4 % had high overall DD and 12 % were categorized as having high risk of DKD. No significant changes were found in DD between T1, T2 and T3. Mean DD differences [SD] between T1 to T2 was 0.02 [0.38], p=0.65 and between T2 and T3 0.01 [0.35], p=0.88. No significant differences in DD changes were found when comparing participants with high vs. low initial DD or when comparing participants in high vs. low risk of DKD. However, few participants had high DD at T1 and few had high risk of DKD.

Conclusions: The study indicated that screening for future risk of DKD does not increase DD in people with T2D. Future studies should explore potential subgroup differences further as well as the mechanisms behind the results.
Original languageEnglish
JournalDiabetes
Volume67
Issue numberSupplement 1
Number of pages1
ISSN0046-0192
DOIs
Publication statusPublished - 1 Jul 2018
EventAmerican Diabetes Association’s 78th Scientific Sessions, ADA - Orange County Convention Center , Orlando, United States
Duration: 22 Jun 201826 Jun 2018
Conference number: 78
https://professional.diabetes.org/meeting/scientific-sessions/78th-scientific-sessions

Conference

ConferenceAmerican Diabetes Association’s 78th Scientific Sessions, ADA
Number78
LocationOrange County Convention Center
CountryUnited States
CityOrlando
Period22/06/201826/06/2018
Internet address

Event

American Diabetes Association’s 78th Scientific Sessions, ADA

22/06/201826/06/2018

Orlando, United States

Event: Conference

ID: 54770634